490 related articles for article (PubMed ID: 22863020)
21. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
[TBL] [Abstract][Full Text] [Related]
22. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
23. Leucine Zipper Downregulated in Cancer-1 Interacts with Clathrin Adaptors to Control Epidermal Growth Factor Receptor (EGFR) Internalization and Gefitinib Response in EGFR-Mutated Non-Small Cell Lung Cancer.
Huang HN; Hung PF; Chen YP; Lee CH
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338651
[TBL] [Abstract][Full Text] [Related]
24. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.
Cragg MS; Kuroda J; Puthalakath H; Huang DC; Strasser A
PLoS Med; 2007 Oct; 4(10):1681-89; discussion 1690. PubMed ID: 17973573
[TBL] [Abstract][Full Text] [Related]
25. JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines.
Kani K; Garri C; Tiemann K; Malihi PD; Punj V; Nguyen AL; Lee J; Hughes LD; Alvarez RM; Wood DM; Joo AY; Katz JE; Agus DB; Mallick P
Mol Cancer Ther; 2017 Aug; 16(8):1645-1657. PubMed ID: 28566434
[TBL] [Abstract][Full Text] [Related]
26. Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations.
Lazzara MJ; Lane K; Chan R; Jasper PJ; Yaffe MB; Sorger PK; Jacks T; Neel BG; Lauffenburger DA
Cancer Res; 2010 May; 70(9):3843-50. PubMed ID: 20406974
[TBL] [Abstract][Full Text] [Related]
27. Hypoxia Promotes Resistance to EGFR Inhibition in NSCLC Cells via the Histone Demethylases, LSD1 and PLU-1.
Lu Y; Liu Y; Oeck S; Glazer PM
Mol Cancer Res; 2018 Oct; 16(10):1458-1469. PubMed ID: 29934325
[TBL] [Abstract][Full Text] [Related]
28. TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation.
Okamoto W; Okamoto I; Tanaka K; Hatashita E; Yamada Y; Kuwata K; Yamaguchi H; Arao T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
Mol Cancer Ther; 2010 Oct; 9(10):2785-92. PubMed ID: 20716641
[TBL] [Abstract][Full Text] [Related]
29. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
[TBL] [Abstract][Full Text] [Related]
30. Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.
Peled N; Wynes MW; Ikeda N; Ohira T; Yoshida K; Qian J; Ilouze M; Brenner R; Kato Y; Mascaux C; Hirsch FR
Cell Oncol (Dordr); 2013 Jul; 36(4):277-88. PubMed ID: 23619944
[TBL] [Abstract][Full Text] [Related]
31. Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib.
Yun M; Kim EO; Lee D; Kim JH; Kim J; Lee H; Lee J; Kim SH
Cell Physiol Biochem; 2014; 34(3):865-72. PubMed ID: 25199820
[TBL] [Abstract][Full Text] [Related]
32. BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells.
Yu Y; Xiao Z; Lei C; Ma C; Ding L; Tang Q; He Y; Chen Y; Chang X; Zhu Y; Zhang H
BMC Cancer; 2023 Aug; 23(1):732. PubMed ID: 37553597
[TBL] [Abstract][Full Text] [Related]
33. YES1 as a potential target to overcome drug resistance in EGFR-deregulated non-small cell lung cancer.
Kook E; Lee J; Kim DH
Arch Toxicol; 2024 May; 98(5):1437-1455. PubMed ID: 38443724
[TBL] [Abstract][Full Text] [Related]
34. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
[TBL] [Abstract][Full Text] [Related]
35. AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines.
Puglisi M; Thavasu P; Stewart A; de Bono JS; O'Brien ME; Popat S; Bhosle J; Banerji U
Lung Cancer; 2014 Aug; 85(2):141-6. PubMed ID: 24957682
[TBL] [Abstract][Full Text] [Related]
36. Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation.
La Monica S; Madeddu D; Tiseo M; Vivo V; Galetti M; Cretella D; Bonelli M; Fumarola C; Cavazzoni A; Falco A; Gervasi A; Lagrasta CA; Naldi N; Barocelli E; Ardizzoni A; Quaini F; Petronini PG; Alfieri R
J Thorac Oncol; 2016 Jul; 11(7):1051-63. PubMed ID: 27006151
[TBL] [Abstract][Full Text] [Related]
37. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
Costa DB; Halmos B; Kumar A; Schumer ST; Huberman MS; Boggon TJ; Tenen DG; Kobayashi S
PLoS Med; 2007 Oct; 4(10):1669-79; discussion 1680. PubMed ID: 17973572
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.
Van Schaeybroeck S; Kyula J; Kelly DM; Karaiskou-McCaul A; Stokesberry SA; Van Cutsem E; Longley DB; Johnston PG
Mol Cancer Ther; 2006 May; 5(5):1154-65. PubMed ID: 16731747
[TBL] [Abstract][Full Text] [Related]
39. Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells.
Tian Y; Zhang Z; Miao L; Yang Z; Yang J; Wang Y; Qian D; Cai H; Wang Y
Oncol Res; 2016; 24(5):295-303. PubMed ID: 27712586
[TBL] [Abstract][Full Text] [Related]
40. TAZ sensitizes EGFR wild-type non-small-cell lung cancer to gefitinib by promoting amphiregulin transcription.
Yuan W; Xu W; Li Y; Jiang W; Li Y; Huang Q; Chen B; Wu S; Wang Y; Song W; Zhao W; Wu J
Cell Death Dis; 2019 Mar; 10(4):283. PubMed ID: 30911072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]